About this Journal Submit a Manuscript Table of Contents
International Journal of Alzheimer’s Disease
Volume 2012 (2012), Article ID 518901, 37 pages
http://dx.doi.org/10.1155/2012/518901
Review Article

Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics

1EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, EuroEspes Chair of Biotechnology and Genomics, Camilo José Cela University, 15165 Bergondo, Spain
2Department of Psychiatry, Medical University of Wroclaw, Pasteura 10, 50-229 Wroclaw, Poland
3Department of Psychiatry and Behavioral Sciences, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita-shi, Osaka 565-0871, Japan

Received 16 June 2011; Accepted 12 November 2011

Academic Editor: Brian Austen

Copyright © 2012 Ramón Cacabelos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Cacabelos, “Psychogeriatric research. A conceptual introduction to geriatric neuroscience,” Psychogeriatrics, vol. 1, pp. 158–188, 2001.
  2. E. Loveman, C. Green, J. Kirby et al., “The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.,” Health Technology Assessment, vol. 10, no. 1, pp. 1–160, 2006. View at Scopus
  3. R. Cacabelos, A. Alvarez, V. Lombardi et al., “Pharmacological treatment of Alzheimer disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomics,” Drugs of Today, vol. 36, no. 7, pp. 415–499, 2000. View at Scopus
  4. R. Cacabelos, “Pharmacogenomics in Alzheimer's disease,” Methods in Molecular Biology, vol. 448, pp. 213–357, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. R. Cacabelos, “Pharmacogenomics and therapeutic strategies for dementia,” Expert Review of Molecular Diagnostics, vol. 9, no. 6, pp. 567–611, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. R. Cacabelos, “Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety, and depression,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 29, pp. 1–91, 2007. View at Scopus
  7. R. Cacabelos, R. Llovo, C. Fraile, and L. Fernández-Novoa, “Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics,” Current Alzheimer Research, vol. 4, no. 4, pp. 479–500, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. S. C. Sim and M. Ingelman-Sundberg, “Pharmacogenomic biomarkers: new tools in current and future drug therapy,” Trends in Pharmacological Sciences, vol. 32, no. 2, pp. 72–81, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. R. Cacabelos, L. Fernandez-Novoa, V. Lombardi, Y. Kubota, and M. Takeda, “Molecular genetics of Alzheimer's disease and aging,” Methods and findings in experimental and clinical pharmacology, vol. 27, pp. 1–573, 2005. View at Scopus
  10. R. Cacabelos and R. Martínez-Bouza, “Genomics and Pharmacogenomics of Dementia,” CNS Neuroscience and Therapeutics, vol. 17, no. 5, pp. 566–576, 2011. View at Publisher · View at Google Scholar · View at PubMed
  11. R. Hwang, R. P. Souza, A. K. Tiwari et al., “Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response,” Pharmacogenomics, vol. 12, no. 2, pp. 277–291, 2011. View at Publisher · View at Google Scholar · View at PubMed
  12. Y. Ji, J. Biernacka, K. Snyder et al., “Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response,” Pharmacogenomics Journal. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. M. De Gregori, M. Allegri, S. De Gregori et al., “How and why to screen for CYP2D6 interindividual variability in patients under pharmacological treatments,” Current Drug Metabolism, vol. 11, no. 3, pp. 276–282, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. J. P. Zhang and A. K. Malhotra, “Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction,” Expert Opinion on Drug Metabolism and Toxicology, vol. 7, no. 1, pp. 9–37, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. I. Johansson and M. Ingelman-Sundberg, “Genetic polymorphism and toxicology—with emphasis on cytochrome P450,” Toxicological Sciences, vol. 120, no. 1, pp. 1–13, 2011. View at Publisher · View at Google Scholar · View at PubMed
  16. V. M. Pratt, B. Zehnbauer, J. A. Wilson et al., “Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and association for molecular pathology collaborative project,” Journal of Molecular Diagnostics, vol. 12, no. 6, pp. 835–846, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. D. Seripa, A. Pilotto, F. Panza, M. G. Matera, and A. Pilotto, “Pharmacogenetics of cytochrome P450 (CYP) in the elderly,” Ageing Research Reviews, vol. 9, no. 4, pp. 457–474, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. W. Aw, I. Ota, Y. Toyoda et al., “Pharmacogenomics of human ABC transporters: detection of clinically important SNPs by SmartAmp2 method,” Current Pharmaceutical Biotechnology, vol. 12, no. 4, pp. 693–704, 2011. View at Publisher · View at Google Scholar
  19. G. Burckhardt and B. C. Burckhardt, “In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy,” Handbook of Experimental Pharmacology, vol. 201, pp. 29–104, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. J. König, “Uptake transporters of the human OATP family: molecular characteristics, substrates, their role in drug-drug interactions, and functional consequences of polymorphisms,” Handbook of Experimental Pharmacology, vol. 201, pp. 1–28, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. V. Haufroid, “Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition,” Current Drug Targets, vol. 12, no. 5, pp. 631–646, 2011. View at Publisher · View at Google Scholar
  22. M. Xu, Q. Xing, S. Li et al., “Pharmacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 34, no. 6, pp. 1026–1032, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. R. Keers and K. J. Aitchison, “Pharmacogenetics of antidepressant response,” Expert Review of Neurotherapeutics, vol. 11, no. 1, pp. 101–125, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. http://www.ncbi.nlm.nih.gov/omim/.
  25. http://www.alzgene.org/.
  26. D. J. Selkoe and M. B. Podlisny, “Deciphering the genetic basis of Alzheimer's disease,” Annual Review of Genomics and Human Genetics, vol. 3, pp. 67–99, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. Y. H. Suh and F. Checler, “Amyloid precursor protein, presenilins, and α-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease,” Pharmacological Reviews, vol. 54, no. 3, pp. 469–525, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Cacabelos, “Donepezil in Alzheimer's disease: from conventional trials to pharmacogenetics,” Neuropsychiatric Disease and Treatment, vol. 3, no. 3, pp. 303–333, 2007. View at Scopus
  29. W. J. Strittmatter, A. M. Saunders, D. Schmechel et al., “Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 5, pp. 1977–1981, 1993. View at Scopus
  30. A. M. Saunders, K. Schmader, J. C. S. Breitner et al., “Apolipoprotein E ε4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases,” Lancet, vol. 342, no. 8873, pp. 710–711, 1993. View at Publisher · View at Google Scholar · View at Scopus
  31. A. M. Saunders, W. J. Strittmatter, D. Schmechel et al., “Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease,” Neurology, vol. 43, no. 8, pp. 1467–1472, 1993. View at Scopus
  32. E. H. Corder, A. M. Saunders, W. J. Strittmatter et al., “Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families,” Science, vol. 261, no. 5123, pp. 921–923, 1993. View at Scopus
  33. E. H. Corder, A. M. Saunders, N. J. Risch et al., “Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease,” Nature Genetics, vol. 7, no. 2, pp. 180–184, 1994. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. F. Schachter, L. Faure-Delanef, F. Guenot et al., “Genetic associations with human longevity at the APOE and ACE loci,” Nature Genetics, vol. 6, no. 1, pp. 29–32, 1994. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. A. D. Roses, “Pharmacogenetics and future drug development and delivery,” Lancet, vol. 355, no. 9212, pp. 1358–1361, 2000. View at Scopus
  36. A. D. Roses, “Pharmacogenetics and the practice of medicine,” Nature, vol. 405, no. 6788, pp. 857–865, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. A. D. Roses, “Pharmacogenetics and drug development: the path to safer and more effective drugs,” Nature Reviews Genetics, vol. 5, no. 9, pp. 645–656, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. N. Filippini, K. P. Ebmeier, B. J. MacIntosh et al., “Differential effects of the APOE genotype on brain function across the lifespan,” NeuroImage, vol. 54, no. 1, pp. 602–610, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. E. Rogaeva, Y. Meng, J. H. Lee et al., “The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease,” Nature Genetics, vol. 39, no. 2, pp. 168–177, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. Y. Meng, J. H. Lee, R. Cheng, P. St George-Hyslop, R. Mayeux, and L. A. Farrer, “Association between SORL1 and Alzheimer's disease in a genome-wide study,” NeuroReport, vol. 18, no. 17, pp. 1761–1764, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. N. Shibata, T. Ohnuma, H. Baba, S. Higashi, K. Nishioka, and H. Arai, “Genetic association between SORL1 polymorphisms and Alzheimer's disease in a Japanese population,” Dementia and Geriatric Cognitive Disorders, vol. 26, no. 2, pp. 161–164, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. R. Cacabelos, L. Fernández-Novoa, R. Martínez-Bouza et al., “Future trends in the pharmacogenomics of brain disorders and dementia: influence of APOE and CYP2D6 variants,” Pharmaceuticals, vol. 3, no. 10, pp. 3040–3100, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Rohe, M. Synowitz, R. Glass, S. M. Paul, A. Nykjaer, and T. E. Willnow, “Brain-derived neurotrophic factor reduces amyloidogenic processing through control of SORLA gene expression,” Journal of Neuroscience, vol. 29, no. 49, pp. 15472–15478, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. Á. Fehér, A. Juhász, Á. Rimanóczy, J. Kálmán, and Z. Janka, “Association between BDNF Val66Met polymorphism and Alzheimer disease, dementia with lewy bodies, and Pick disease,” Alzheimer Disease and Associated Disorders, vol. 23, no. 3, pp. 224–228, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. Y. Wang, P. M. Rogers, K. R. Stayrook et al., “The selective Alzheimer's disease indicator-1 gene (Seladin-1/DHCR24) is a liver X receptor target gene,” Molecular Pharmacology, vol. 74, no. 6, pp. 1716–1721, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. A. Peri and M. Serio, “Neuroprotective effects of the Alzheimer's disease-related gene seladin-1,” Journal of Molecular Endocrinology, vol. 41, no. 5-6, pp. 251–261, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. A. E. Sanders, C. Wang, M. Katz et al., “Association of a functional polymorphism in the cholesteryl ester transfer protein (CETP) gene with memory decline and incidence of dementia,” Journal of the American Medical Association, vol. 303, no. 2, pp. 150–158, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. B. A. J. Schaffer, L. Bertram, B. L. Miller et al., “Association of GSK3B with Alzheimer disease and frontotemporal dementia,” Archives of Neurology, vol. 65, no. 10, pp. 1368–1374, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. W. C. Hsu, H. K. Wang, L. C. Lee et al., “Promoter polymorphisms modulating HSPA5 expression may increase susceptibility to Taiwanese Alzheimer's disease,” Journal of Neural Transmission, vol. 115, no. 11, pp. 1537–1543, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. Y. Chen, L. Jia, C. Wei, F. Wang, H. Lv, and J. Jia, “Association between polymorphisms in the apolipoprotein D gene and sporadic Alzheimer's disease,” Brain Research, vol. 1233, no. C, pp. 196–202, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. U. Dreses-Werringloer, J. C. Lambert, V. Vingtdeux et al., “A polymorphism in CALHM1 influences Ca2+ homeostasis, Aβ levels, and Alzheimer’s disease risk,” Cell, vol. 133, no. 7, pp. 1149–1161, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. D. Harold, R. Abraham, P. Hollingworth et al., “Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease,” Nature Genetics, vol. 41, no. 10, pp. 1088–1093, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. J. C. Lambert, S. Heath, G. Even et al., “Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease,” Nature Genetics, vol. 41, no. 10, pp. 1094–1099, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. G. Jun, A. C. Naj, G. W. Beecham et al., “Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes,” Archives of Neurology, vol. 67, no. 12, pp. 1473–1484, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. S. Seshadri, A. L. Fitzpatrick, M. A. Ikram et al., “Genome-wide analysis of genetic loci associated with Alzheimer disease,” Journal of the American Medical Association, vol. 303, no. 18, pp. 1832–1840, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. P. L. Kramer, H. Xu, R. L. Woltjer et al., “Alzheimer disease pathology in cognitively healthy elderly: a genome-wide study,” Neurobiology of Aging, vol. 32, no. 12, pp. 2113–2122, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. M. S. Durakoglugil, Y. Chen, C. L. White, E. T. Kavalali, and J. Herz, “Reelin signaling antagonizes β-amyloid at the synapse,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 37, pp. 15938–15943, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. A. D. Roses, M. W. Lutz, H. Amrine-Madsen et al., “A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease,” Pharmacogenomics Journal, vol. 10, no. 5, pp. 375–384, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. M. W. Lutz, D. G. Crenshaw, A. M. Saunders, and A. D. Roses, “Genetic variation at a single locus and age of onset for Alzheimer's disease,” Alzheimer's and Dementia, vol. 6, no. 2, pp. 125–131, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. A. D. Roses, “An inherited variable poly-T repeat genotype in TOMM40 in Alzheimer disease,” Archives of Neurology, vol. 67, no. 5, pp. 536–541, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. K. Ohe and A. Mayeda, “HMGA1a trapping of U1 snRNP at an authentic 5′ splice site induces aberrant exon skipping in sporadic Alzheimer's disease,” Molecular and Cellular Biology, vol. 30, no. 9, pp. 2220–2228, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. B. J. Kelley, W. Haidar, B. F. Boeve et al., “Alzheimer disease-like phenotype associated with the c.154delA mutation in progranulin,” Archives of Neurology, vol. 67, no. 2, pp. 171–177, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. C. E. Yu, T. D. Bird, L. M. Bekris et al., “The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration,” Archives of Neurology, vol. 67, no. 2, pp. 161–170, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. M. A. Smach, B. Charfeddine, L. B. Othman et al., “-1154G/A and -2578C/A polymorphisms of the vascular endothelial growth factor gene in Tunisian Alzheimer patients in relation to β-amyloid (1–42) and total tau protein,” Neuroscience Letters, vol. 472, no. 2, pp. 139–142, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. Z. Jin, C. Luxiang, Z. Huadong et al., “Endothelin-converting enzyme-1 promoter polymorphisms and susceptibility to sporadic late-onset Alzheimer's disease in a Chinese population,” Disease Markers, vol. 27, no. 5, pp. 211–215, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. S. Xue, L. Jia, and J. Jia, “Association between somatostatin gene polymorphisms and sporadic Alzheimer's disease in Chinese population,” Neuroscience Letters, vol. 465, no. 2, pp. 181–183, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. K. Li, D. Dai, B. Zhao et al., “Association between the RAGE G82S polymorphism and Alzheimer's disease,” Journal of Neural Transmission, vol. 117, no. 1, pp. 97–104, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. K. Takuma, F. Fang, W. Zhang et al., “RAGE-mediated signaling contributes to intraneuronal transport of amyloid-β and neuronal dysfunction,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 47, pp. 20021–20026, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. N. Shibata, T. Ohnuma, H. Baba, and H. Arai, “Genetic association analysis between TDP-43 polymorphisms and Alzheimer's disease in a Japanese population,” Dementia and Geriatric Cognitive Disorders, vol. 28, no. 4, pp. 325–329, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. F. Listì, C. Caruso, D. Lio et al., “Role of cyclooxygenase-2 and 5-lipoxygenase polymorphisms in Alzheimer's disease in a population from Northern Italy: implication for pharmacogenomics,” Journal of Alzheimer's Disease, vol. 19, no. 2, pp. 551–557, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. F. R. Guerini, C. Tinelli, E. Calabrese et al., “HLA-A*01 is associated with late onset of Alzheimer's disease in Italian patients,” International Journal of Immunopathology and Pharmacology, vol. 22, no. 4, pp. 991–999, 2009. View at Scopus
  72. P. Vural, S. Deǧirmenciolu, H. Parildar-Karpuzoǧlu et al., “The combinations of TNF-308 and IL-6 -174 or IL-10 -1082 genes polymorphisms suggest an association with susceptibility to sporadic late-onset Alzheimer's disease,” Acta Neurologica Scandinavica, vol. 120, no. 6, pp. 396–401, 2009. View at Publisher · View at Google Scholar · View at PubMed
  73. C. Capurso, V. Solfrizzi, A. M. Colacicco et al., “Interleukin 6-174 G/C promoter and variable number of tandem repeats (VNTR) gene polymorphisms in sporadic Alzheimer's disease,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 34, no. 1, pp. 177–182, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. J. T. Yu, J. H. Song, N. D. Wang et al., “Implication of IL-33 gene polymorphism in Chinese patients with Alzheimer's disease,” Neurobiology of Aging. In press. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. H. T. Butler, D. R. Warden, E. Hogervorst, J. Ragoussis, A. D. Smith, and D. J. Lehmann, “Association of the aromatase gene with Alzheimer's disease in women,” Neuroscience Letters, vol. 468, no. 3, pp. 202–206, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. S. Vepsäläinen, S. Helisalmi, A. Mannermaa, T. Pirttilä, H. Soininen, and M. Hiltunen, “Combined risk effects of IDE and NEP gene variants on Alzheimer disease,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 80, no. 11, pp. 1268–1270, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. L. Zhong, Q. Dong-Hai, L. Hong-Ying, and L. Qing-Feng, “Analysis of the nicastrin promoter rs10752637 polymorphism and its association with Alzheimer's disease,” European Journal of Neuroscience, vol. 30, no. 9, pp. 1831–1836, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  78. G. Laumet, V. Petitprez, A. Sillaire et al., “A study of the association between the ADAM12 and SH3PXD2A (SH3MD1) genes and Alzheimer's disease,” Neuroscience Letters, vol. 468, no. 1, pp. 1–2, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. V. Leduc, L. Théroux, D. Dea, Y. Robitaille, and J. Poirier, “Involvement of paraoxonase 1 genetic variants in Alzheimer's disease neuropathology,” European Journal of Neuroscience, vol. 30, no. 9, pp. 1823–1830, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. H. P. Liu, W. Y. Lin, S. H. Liu et al., “Genetic variation in N-methyl-D-aspartate receptor subunit NR3A but not NR3B influences susceptibility to Alzheimer’s disease,” Dementia and Geriatric Cognitive Disorders, vol. 28, no. 6, pp. 521–527, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  81. E. Di Maria, C. Bonvicini, C. Bonomini, A. Alberici, O. Zanetti, and M. Gennarelli, “Genetic variation in the G720/G30 gene locus (DAOA) influences the occurrence of psychotic symptoms in patients with Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 18, no. 4, pp. 953–960, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. M. F. Martínez, X. E. Martín, L. G. Alcelay et al., “The COMT Val158 met polymorphism as an associated risk factor for Alzheimer disease and mild cognitive impairment in APOE 4 carriers,” BMC Neuroscience, vol. 10, article no. 125, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  83. A. Maruszak, K. Safranow, K. Gustaw et al., “PIN1 gene variants in Alzheimer's disease,” BMC Medical Genetics, vol. 10, article 115, 2009. View at Scopus
  84. K. A. B. Kellett and N. M. Hooper, “Prion protein and Alzheimer disease,” Prion, vol. 3, no. 4, pp. 190–194, 2009. View at Scopus
  85. S. E. Lloyd, M. Rossor, N. Fox, S. Mead, and J. Collinge, “HECTD2, a candidate susceptibility gene for Alzheimer's disease on 10q,” BMC Medical Genetics, vol. 10, article no. 90, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  86. K. Ahn, J. H. Song, D. K. Kim, M. H. Park, S. A. Jo, and Y. H. Koh, “Ubc9 gene polymorphisms and late-onset Alzheimer's disease in the Korean population: a genetic association study,” Neuroscience Letters, vol. 465, no. 3, pp. 272–275, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  87. S. Persengiev, I. Kondova, N. Otting, A. H. Koeppen, and R. E. Bontrop, “Genome-wide analysis of miRNA expression reveals a potential role for miR-144 in brain aging and spinocerebellar ataxia pathogenesis,” Neurobiology of Aging, vol. 32, no. 12, pp. 2316.e17–2316.e27, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  88. K. Bettens, N. Brouwers, H. Van Miegroet et al., “Follow-up study of susceptibility loci for Alzheimer's disease and onset age identified by genome-wide association,” Journal of Alzheimer's Disease, vol. 19, no. 4, pp. 1169–1175, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  89. J. J. Donkin, S. Stukas, V. Hirsch-Reinshagen et al., “ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice,” Journal of Biological Chemistry, vol. 285, no. 44, pp. 34144–34154, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  90. B. Kuerban, N. Shibata, M. Komatsu, T. Ohnuma, and H. Arai, “Genetic association between PLTP gene polymorphisms and Alzheimer's disease in a Japanese population,” Dementia and Geriatric Cognitive Disorders, vol. 30, no. 1, pp. 78–82, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  91. L. Bertram and R. E. Tanzi, “Genome-wide association studies in Alzheimer's disease,” Human Molecular Genetics, vol. 18, no. R2, pp. R137–R145, 2009.
  92. M. T. Lin, D. K. Simon, C. H. Ahn, L. M. Kim, and M. Flint Beal, “High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain,” Human Molecular Genetics, vol. 11, no. 2, pp. 133–145, 2002. View at Scopus
  93. C. M. Pinho, B. F. Björk, N. Alikhani et al., “Genetic and biochemical studies of SNPs of the mitochondrial Aβ-degrading protease, hPreP,” Neuroscience Letters, vol. 469, no. 2, pp. 204–208, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  94. M. Vitali, E. Venturelli, D. Galimberti, L. Benerini Gatta, E. Scarpini, and D. Finazzi, “Analysis of the genes coding for subunit 10 and 15 of cytochrome c oxidase in Alzheimer's disease,” Journal of Neural Transmission, vol. 116, no. 12, pp. 1635–1641, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  95. S. Takasaki, “Mitochondrial haplogroups associated with Japanese Alzheimer's patients,” Journal of Bioenergetics and Biomembranes, vol. 41, no. 5, pp. 407–410, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  96. A. Santoro, V. Balbi, E. Balducci et al., “Evidence for sub-haplogroup H5 of mitochondrial DNA as a risk factor for late onset Alzheimer's disease,” PLoS One, vol. 5, no. 8, Article ID e12037, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  97. R. Cacabelos and M. Takeda, “Pharmacogenomics, nutrigenomics and future therapeutics in Alzheimer’s disease,” Drugs Future, vol. 31, supplement B, pp. 5–146, 2006.
  98. M. Zhang, M. Poplawski, K. Yen et al., “Role of CBP and SATB-1 in aging, dietary restriction, and insulin-like signaling,” PLoS Biology, vol. 7, no. 11, Article ID e1000245, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  99. J. N. Lukens, V. Van Deerlin, C. M. Clark, S. X. Xie, and F. B. Johnson, “Comparisons of telomere lengths in peripheral blood and cerebellum in Alzheimer's disease,” Alzheimer's and Dementia, vol. 5, no. 6, pp. 463–469, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  100. D. Zekry, F. R. Herrmann, I. Irminger-Finger et al., “Telomere length and ApoE polymorphism in mild cognitive impairment, degenerative and vascular dementia,” Journal of the Neurological Sciences, vol. 299, no. 1-2, pp. 108–111, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  101. C. N. G. Anderson and S. G. N. Grant, “High throughput protein expression screening in the nervous system—needs and limitations,” Journal of Physiology, vol. 575, no. 2, pp. 367–372, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  102. X. Xu, M. Zhan, W. Duan et al., “Gene expression atlas of the mouse central nervous system: impact and interactions of age, energy intake and gender,” Genome Biology, vol. 8, no. 11, article no. R234, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  103. M. A. Mastrangelo and W. J. Bowers, “Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice,” BMC Neuroscience, vol. 9, article no. 81, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  104. J. J. Rodríguez, V. C. Jones, M. Tabuchi et al., “Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer's Disease,” PLoS One, vol. 3, no. 8, article e2935, 2008. View at Publisher · View at Google Scholar · View at PubMed
  105. R. Cacabelos, “Pharmacogenomic biomarkers in neuropsychiatry: the path to personalized medicine in mental disorders,” in The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes, M. S. Ritsner, Ed., vol. 4, pp. 3–63, Springer, New York, NY, USA, 2009.
  106. N. Berry, V. Jobanputra, and H. Pal, “Molecular genetics of schizophrenia: a critical review,” Journal of Psychiatry and Neuroscience, vol. 28, no. 6, pp. 415–429, 2003. View at Scopus
  107. T. Kato, “Molecular genetics of bipolar disorder and depression,” Psychiatry and Clinical Neurosciences, vol. 61, no. 1, pp. 3–19, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  108. R. Cacabelos, “Pharmacogenomics for the treatment of dementia,” Annals of Medicine, vol. 34, no. 5, pp. 357–379, 2002. View at Publisher · View at Google Scholar · View at Scopus
  109. R. Cacabelos, “The application of functional genomics to Alzheimer's disease,” Pharmacogenomics, vol. 4, no. 5, pp. 597–621, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  110. R. Cacabelos, “Pharmacogenomics and therapeutic prospects in Alzheimer's disease,” Expert Opinion on Pharmacotherapy, vol. 6, no. 12, pp. 1967–1987, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  111. R. Cacabelos, “Pharmacogenomics, nutrigenomics and therapeutic optimization in Alzheimer’s disease,” Aging Health, vol. 1, pp. 303–348, 2005.
  112. R. Cacabelos, “Pharmacogenomics and therapeutic prospects in dementia,” European Archives of Psychiatry and Clinical Neuroscience, vol. 258, no. 1, pp. 28–47, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  113. R. Cacabelos, “Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease,” Molecular Diagnosis and Therapy, vol. 11, no. 6, pp. 385–405, 2007. View at Scopus
  114. R. Cacabelos, L. Fernández-Novoa, V. Pichel, V. Lombardi, Y. Kubota, and M. Takeda, “Pharmacogenomic studies with a combination therapy in Alzheimer’s disease,” in Molecular Neurobiology of Alzheimer Disease and Related Disorders, M. Takeda, T. Tanaka, and R. Cacabelos, Eds., pp. 94–107, Karger, Basel, Switzerland, 2004.
  115. R. Cacabelos, “Pharmacogenomics in Alzheimer’s disease,” in Pharmacogenomics and Personalized Medicine, N. Cohen, Ed., pp. 317–368, Humana Press, Totowa, NJ, USA, 2008.
  116. P. A. Thomann, A. S. Roth, V. Dos Santos, P. Toro, M. Essig, and J. Schröder, “Apolipoprotein E polymorphism and brain morphology in mild cognitive impairment,” Dementia and Geriatric Cognitive Disorders, vol. 26, no. 4, pp. 300–305, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  117. S. B. Sando, S. Melquist, A. Cannon et al., “APOE ε4 lowers age at onset and is a high risk factor for Alzheimer's disease; a case control study from central Norway,” BMC Neurology, vol. 8, article 9, 2008. View at Publisher · View at Google Scholar · View at PubMed
  118. M. Thambisetty, L. Beason-Held, Y. An, M. A. Kraut, and S. M. Resnick, “APOE ε4 genotype and longitudinal changes in cerebral blood flow in normal aging,” Archives of Neurology, vol. 67, no. 1, pp. 93–98, 2010. View at Publisher · View at Google Scholar · View at PubMed
  119. R. Cacabelos, L. Fernández-Novoa, L. Corzo, V. Pichel, V. Lombardi, and Y. Kubota, “Genomics and phenotypic profiles in dementia: implications for pharmacological treatment,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 26, no. 6, pp. 421–444, 2004.
  120. R. Cacabelos, L. Fernández-Novoa, V. Lombardi, L. Corzo, V. Pichel, and Y. Kubota, “Cerebrovascular risk factors in Alzheimer's disease: brain hemodynamics and pharmacogenomic implications,” Neurological Research, vol. 25, no. 6, pp. 567–580, 2003. View at Publisher · View at Google Scholar · View at Scopus
  121. A. E. Roher, C. L. Maarouf, L. I. Sue, Y. Hu, J. Wilson, and T. G. Beach, “Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease,” Biomarkers, vol. 14, no. 7, pp. 493–501, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  122. E. Giacobini, “Cholinesterases in human brain: the effect of cholinesterase inhibitors on Alzheimer's disease and related disorders,” in The Brain Cholinergic System in Health and Disease, E. Giacobini and G. Pepeu, Eds., pp. 235–264, Informa Healthcare, Oxon, UK, 2006.
  123. B. Reisberg, R. Doody, A. Stöffler, F. Schmitt, S. Ferris, and H. J. Möbius, “Memantine in moderate-to-severe Alzheimer's disease,” New England Journal of Medicine, vol. 348, no. 14, pp. 1333–1341, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  124. D. B. Schenk, P. Seubert, M. Grundman, and R. Black, “Aβ immunotherapy: lessons learned for potential treatment of Alzheimer's disease,” Neurodegenerative Diseases, vol. 2, no. 5, pp. 255–260, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  125. T. Wisniewski and A. Boutajangout, “Vaccination as a therapeutic approach to Alzheimer's disease,” Mount Sinai Journal of Medicine, vol. 77, no. 1, pp. 17–31, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  126. B. De Strooper, R. Vassar, and T. Golde, “The secretases: enzymes with therapeutic potential in Alzheimer disease,” Nature Reviews Neurology, vol. 6, no. 2, pp. 99–107, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  127. C. C. Shelton, L. Zhu, D. Chau et al., “Modulation of γ-secretase specificity using small molecule allosteric inhibitors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 48, pp. 20228–20233, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  128. D. Lambracht-Washington, B. -X. Qu, M. Fu, T. N. Eagar, O. Stüve, and R. N. Rosenberg, “DNA β-amyloid1-42 trimer immunization for Alzheimer disease in a wild-type mouse model,” Journal of the American Medical Association, vol. 302, no. 16, pp. 1796–1802, 2009. View at Publisher · View at Google Scholar · View at PubMed
  129. F. Lang and A. Görlach, “Heterocyclic indazole derivatives as SGK1 inhibitors, WO2008138448,” Expert Opinion on Therapeutic Patents, vol. 20, no. 1, pp. 129–135, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  130. C. S. Frigerio, T. L. Kukar, A. Fauq, P. C. Engel, T. E. Golde, and D. M. Walsh, “An NSAID-like compound, FT-9, preferentially inhibits γ-secretase cleavage of the amyloid precursor protein compared to its effect on amyloid precursor-like protein,” Biochemistry, vol. 48, no. 46, pp. 10894–10904, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  131. R. J. Boado, J. Z. Lu, E. K.-W. Hui, and W. M. Pardridge, “IgG-single chain Fv fusion protein therapeutic for Alzheimer's disease: expression in CHO cells and pharmacokinetics and brain delivery in the Rhesus monkey,” Biotechnology and Bioengineering, vol. 105, no. 3, pp. 627–635, 2010. View at Publisher · View at Google Scholar · View at PubMed
  132. H. Adachi, M. Katsuno, M. Waza, M. Minamiyama, F. Tanaka, and G. Sobue, “Heat shock proteins in neurodegenerative diseases: pathogenic roles and therapeutic implications,” International Journal of Hyperthermia, vol. 25, no. 8, pp. 647–654, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  133. M. Kilgore, C. A. Miller, D. M. Fass et al., “Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease,” Neuropsychopharmacology, vol. 35, no. 4, pp. 870–880, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  134. T. Hamaguchi, K. Ono, A. Murase, and M. Yamada, “Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid-β aggregation pathway,” American Journal of Pathology, vol. 175, no. 6, pp. 2557–2565, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  135. S. Kalinin, J. C. Richardson, and D. L. Feinstein, “A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer's disease,” Current Alzheimer Research, vol. 6, no. 5, pp. 431–437, 2009. View at Publisher · View at Google Scholar · View at Scopus
  136. R. Roshan, T. Ghosh, V. Scaria, and B. Pillai, “MicroRNAs: novel therapeutic targets in neurodegenerative diseases,” Drug Discovery Today, vol. 14, no. 23-24, pp. 1123–1129, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  137. M. M. Maxwell, “RNAi applications in therapy development for neurodegenerative disease,” Current Pharmaceutical Design, vol. 15, no. 34, pp. 3977–3991, 2009. View at Publisher · View at Google Scholar · View at Scopus
  138. A. D. Roses, “The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B*5701 as a model of safety,” Neuropsychopharmacology, vol. 34, no. 1, pp. 6–17, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  139. A. D. Roses, A. M. Saunders, Y. Huang, J. Strum, K. H. Weisgraber, and R. W. Mahley, “Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease),” Pharmacogenomics Journal, vol. 7, no. 1, pp. 10–28, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  140. M. E. Risner, A. M. Saunders, J. F. Altman, et al., “Rosiglitazone in Alzheimer’s disease study group. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease,” Pharmacogenomics Journal, vol. 6, pp. 246–254, 2006.
  141. J. Poirier, M. C. Delisle, R. Quirion et al., “Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 26, pp. 12260–12264, 1995. View at Publisher · View at Google Scholar · View at Scopus
  142. O. Almkvist, V. Jelic, K. Amberla, E. Hellström-Lindahl, L. Meurling, and A. Nordberg, “Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients,” Dementia and Geriatric Cognitive Disorders, vol. 12, no. 1, pp. 22–32, 2001. View at Publisher · View at Google Scholar
  143. M. Sjögren, C. Hesse, H. Basun et al., “Tacrine and rate of progression in Alzheimer's disease—relation to ApoE allele genotype,” Journal of Neural Transmission, vol. 108, no. 4, pp. 451–458, 2001. View at Publisher · View at Google Scholar · View at Scopus
  144. B. Borroni, F. Colciaghi, L. Pastorino et al., “ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model,” European Neuropsychopharmacology, vol. 12, no. 3, pp. 195–200, 2002. View at Publisher · View at Google Scholar · View at Scopus
  145. J. Aerssens, P. Raeymaekers, S. Lilienfeld, H. Geerts, F. Konings, and W. Parys, “APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease,” Dementia and Geriatric Cognitive Disorders, vol. 12, no. 2, pp. 69–77, 2001. View at Publisher · View at Google Scholar · View at Scopus
  146. M. A. Raskind, E. R. Peskind, T. Wessel, and W. Yuan, “Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension,” Neurology, vol. 54, no. 12, pp. 2261–2268, 2000.
  147. T. Babić, D. M. Lakušić, J. Sertić, M. Petrovečki, and A. Stavljenić-Rukavina, “ApoE genotyping and response to galanthamine in Alzheimer's disease—a real life retrospective study,” Collegium Antropologicum, vol. 28, no. 1, pp. 199–204, 2004.
  148. S. H. MacGowan, G. K. Wilcock, and M. Scott, “Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease,” International Journal of Geriatric Psychiatry, vol. 13, no. 9, pp. 625–630, 1998. View at Publisher · View at Google Scholar · View at Scopus
  149. A. S. Rigaud, L. Traykov, L. Caputo, et al., “The apolipoprotein E epsilon 4 allele and the response to tacrine therapy in Alzheimer’s disease,” European Journal of Neurology, vol. 7, pp. 255–258, 2000.
  150. A. S. Rigaud, L. Traykov, F. Latour, R. Couderc, F. Moulin, and F. Forette, “Presence or absence of at least one ε4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease,” Pharmacogenetics, vol. 12, no. 5, pp. 415–420, 2002. View at Publisher · View at Google Scholar · View at Scopus
  151. R. C. Petersen, G. E. Smith, S. C. Waring, R. J. Ivnik, E. G. Tangalos, and E. Kokmen, “Mild cognitive impairment: clinical characterization and outcome,” Archives of Neurology, vol. 56, no. 3, pp. 303–308, 1999. View at Scopus
  152. A. Bizzarro, C. Marra, A. Acciarri et al., “Apolipoprotein E ε4 allele differentiates the clinical response to donepezil in Alzheimer's disease,” Dementia and Geriatric Cognitive Disorders, vol. 20, no. 4, pp. 254–261, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  153. X. A. Álvarez, R. Mouzo, Pichel et al., “Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 21, no. 9, pp. 633–644, 1999.
  154. X. A. Álvarez, V. Pichel, P. Pérez et al., “Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 22, no. 7, pp. 585–594, 2000.
  155. A. M. Saunders, M. K. Trowers, R. A. Shimkets et al., “The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection,” Biochimica et Biophysica Acta, vol. 1502, no. 1, pp. 85–94, 2000. View at Publisher · View at Google Scholar
  156. V. R. M. Lombardi and R. Cacabelos, “E-SAR-94010: a marine fish extract obtained by advanced biotechnological methods,” Drugs of the Future, vol. 24, no. 2, pp. 167–176, 1999. View at Scopus
  157. R. Cacabelos, A. I. Vallejo, V. Lombardi, L. Fernández-Novoa, and V. Pichel, “E-SAR-94010 (LipoEsar®): a pleiotropic lipoprotein compound with powerful anti-atheromatous and lipid lowering effects,” CNS Drug Reviews, vol. 10, pp. 200–201, 2004.
  158. R. Cacabelos, Pharmacogenomics and nutraceuticals. Scientific progress and pharmaceutical development, Ebiotec Foundation, Coruña, Spain, 2004.
  159. G. W. Rebeck, M. J. LaDu, S. Estus, G. Bu, and E. J. Weeber, “The generation and function of soluble apoE receptors in the CNS,” Molecular Neurodegeneration, vol. 1, no. 1, article no. 15, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  160. P. G. Ulery, J. Beers, I. Mikhailenko et al., “Modulation of β-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer's disease,” Journal of Biological Chemistry, vol. 275, no. 10, pp. 7410–7415, 2000. View at Publisher · View at Google Scholar · View at Scopus
  161. C. U. Pietrzik, T. Busse, D. E. Merriam, S. Weggen, and E. H. Koo, “The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing,” EMBO Journal, vol. 21, no. 21, pp. 5691–5700, 2002. View at Publisher · View at Google Scholar · View at Scopus
  162. J. A. Cam and G. Bu, “Modulation of β-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family,” Molecular Neurodegeneration, vol. 1, no. 1, article no. 8, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  163. O. M. Andersen, J. Reiche, V. Schmidt et al., “Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 38, pp. 13461–13466, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  164. O. M. Andersen, V. Schmidt, R. Spoelgen et al., “Molecular dissection of the interaction between amyloid precursor protein and its neuronal trafficking receptor SorLA/LR11,” Biochemistry, vol. 45, no. 8, pp. 2618–2628, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  165. R. Spoelgen, C. A. F. Von Arnim, A. V. Thomas et al., “Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and β-secretase β-site APP-cleaving enzyme,” Journal of Neuroscience, vol. 26, no. 2, pp. 418–428, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  166. R. Cacabelos, L. Fernández-Novoa, L. Corzo et al., “Phenotypic profiles and functional genomics in Alzheimer's disease and in dementia with a vascular component,” Neurological Research, vol. 26, no. 5, pp. 459–480, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  167. A. J. Lusis, “Atherosclerosis,” Nature, vol. 407, no. 6801, pp. 233–241, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  168. S. Engelborghs, B. Dermaut, J. Goeman et al., “Prospective Belgian study of neurodegenerative and vascular dementia: APOE genotype effects,” Journal of Neurology Neurosurgery and Psychiatry, vol. 74, no. 8, pp. 1148–1151, 2003. View at Publisher · View at Google Scholar
  169. J. Tian, J. Shi, K. Bailey, C. L. Lendon, S. M. Pickering-Brown, and D. M.A. Mann, “Association between apolipoprotein E e4 allele and arteriosclerosis, cerebral amyloid angiopathy, and cerebral white matter damage in Alzheimer's disease,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 75, no. 5, pp. 696–699, 2004. View at Publisher · View at Google Scholar
  170. R. L. Raffaï and K. H. Weisgraber, “Cholesterol: from heart attacks to Alzheimer's disease,” Journal of Lipid Research, vol. 44, no. 8, pp. 1423–1430, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  171. F. R. Maxfield and D. Wüstner, “Intracellular cholesterol transport,” Journal of Clinical Investigation, vol. 110, no. 7, pp. 891–898, 2002. View at Publisher · View at Google Scholar · View at Scopus
  172. L. Puglielli, R. E. Tanzi, and D. M. Kovacs, “Alzheimer's disease: the cholesterol connection,” Nature Neuroscience, vol. 6, no. 4, pp. 345–351, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  173. S. Bodovitz and W. L. Klein, “Cholesterol modulates α-secretase cleavage of amyloid precursor protein,” Journal of Biological Chemistry, vol. 271, no. 8, pp. 4436–4440, 1996. View at Publisher · View at Google Scholar · View at Scopus
  174. E. R. Frears, D. J. Stephens, C. E. Walters, H. Davies, and B. M. Austen, “The role of cholesterol in the biosynthesis of β-amyloid,” NeuroReport, vol. 10, no. 8, pp. 1699–1705, 1999. View at Scopus
  175. M. Simons, P. Keller, B. De Strooper, K. Beyreuther, C. G. Dotti, and K. Simons, “Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 11, pp. 6460–6464, 1998. View at Publisher · View at Google Scholar · View at Scopus
  176. H. Runz, J. Rietdorf, I. Tomic et al., “Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells,” Journal of Neuroscience, vol. 22, no. 5, pp. 1679–1689, 2002. View at Scopus
  177. S. Wahrle, P. Das, A. C. Nyborg et al., “Cholesterol-dependent γ-secretase activity in buoyant cholesterol-rich membrane microdomains,” Neurobiology of Disease, vol. 9, no. 1, pp. 11–23, 2002. View at Publisher · View at Google Scholar · View at PubMed
  178. L. M. Refolo, M. A. Pappolla, B. Malester et al., “Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model,” Neurobiology of Disease, vol. 7, no. 4, pp. 321–331, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  179. J. A. Levin-Allerhand, C. E. Lominska, and J. D. Smith, “Increased amyloid-β levels in APPSWE transgenic mice treated chronically with a physiological high-fat high-cholesterol diet,” Journal of Nutrition, Health and Aging, vol. 6, no. 5, pp. 315–319, 2002. View at Scopus
  180. B. Austen, G. Christodoulou, and J. E. Terry, “Relation between cholesterol levels, statins and Alzheimer's disease in the human population,” Journal of Nutrition, Health and Aging, vol. 6, no. 6, pp. 377–382, 2002. View at Scopus
  181. K. Ishii, T. Tokuda, T. Matsushima et al., “Pravastatin at 10 mg/day does not decrease plasma levels of either amyloid-β (Aβ) 40 or Aβ 42 in humans,” Neuroscience Letters, vol. 350, no. 3, pp. 161–164, 2003. View at Publisher · View at Google Scholar
  182. T. Tokuda, A. Tamaoka, S. Matsuno et al., “Plasma levels of amyloid β proteins did not differ between subjects taking statins and those not taking statins,” Annals of Neurology, vol. 49, no. 4, pp. 546–547, 2001. View at Publisher · View at Google Scholar · View at Scopus
  183. X. Bi, M. Baudry, J. Liu et al., “Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia,” Journal of Biological Chemistry, vol. 279, no. 46, pp. 48238–48245, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  184. M. A. Pappolla, T. K. Bryant-Thomas, D. Herbert et al., “Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology,” Neurology, vol. 61, no. 2, pp. 199–205, 2003. View at Scopus
  185. Y.-M. Kuo, M. R. Emmerling, C. L. Bisgaier et al., “Elevated low-density lipoprotein in Alzheimer's disease correlates with brain aβ 1–42 levels,” Biochemical and Biophysical Research Communications, vol. 252, no. 3, pp. 711–715, 1998. View at Publisher · View at Google Scholar · View at PubMed
  186. C. P. Libeu, S. Lund-Katz, M. C. Phillips et al., “New insights into the heparan sulfate proteoglycan-binding activity of apolipoprotein E,” Journal of Biological Chemistry, vol. 276, no. 42, pp. 39138–39144, 2001. View at Publisher · View at Google Scholar · View at PubMed
  187. B. Borroni, S. Archetti, C. Agosti et al., “Intronic CYP46 polymorphism along with ApoE genotype in sporadic Alzheimer disease: from risk factors to disease modulators,” Neurobiology of Aging, vol. 25, no. 6, pp. 747–751, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  188. B. Wang, C. Zhang, W. Zheng et al., “Association between a T/C polymorphism in intron 2 of cholesterol 24S-hydroxylase gene and Alzheimer's disease in Chinese,” Neuroscience Letters, vol. 369, no. 2, pp. 104–107, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  189. A. Papassotiropoulos, J. R. Streffer, M. Tsolaki et al., “Increased brain β-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism,” Archives of Neurology, vol. 60, no. 1, pp. 29–35, 2003.
  190. A. Johansson, H. Katzov, H. Zetterberg et al., “Variants of CYP46A1 may interact with age and APOE to influence CSF Aβ42 levels in Alzheimer's disease,” Human Genetics, vol. 114, no. 6, pp. 581–587, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  191. V. Hirsch-Reinshagen, S. Zhou, B. L. Burgess et al., “Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain,” Journal of Biological Chemistry, vol. 279, no. 39, pp. 41197–41207, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  192. H. Katzov, K. Chalmers, J. Palmgren et al., “Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to β-amylolid metabolism,” Human Mutation, vol. 23, no. 4, pp. 358–367, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  193. S. V. Frankfort, V. D. Dooderman, R. Bakker, et al., “ABCA1 genotypes and haplotypes in patients with dementia and age-matched non-demented control patients,” Molecular Neurodegeneration, vol. 1, p. 13, 2006.
  194. S. Macé, E. Cousin, S. Ricard et al., “ABCA2 is a strong genetic risk factor for early-onset Alzheimer's disease,” Neurobiology of Disease, vol. 18, no. 1, pp. 119–125, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  195. M. A. Wollmer, E. Kapaki, M. Hersberger et al., “Ethnicity-dependent genetic association of ABCA2 with sporadic Alzheimer's disease,” American Journal of Medical Genetics B, vol. 141, no. 5, pp. 534–536, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  196. M. Dean, “The genetics of ATP-binding cassette transporters,” Methods in Enzymology, vol. 400, pp. 409–429, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  197. S. E. Wahrle, H. Jiang, M. Parsadanian et al., “ABCA1 is required for normal central nervous system apoE levels and for lipidation of astrocyte-secreted apoE,” Journal of Biological Chemistry, vol. 279, no. 39, pp. 40987–40993, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  198. V. Hirsch-Reinshagen, L. F. Maia, B. L. Burgess et al., “The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease,” Journal of Biological Chemistry, vol. 280, no. 52, pp. 43243–43256, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  199. R. Koldamova, M. Staufenbiel, and I. Lefterov, “Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice,” Journal of Biological Chemistry, vol. 280, no. 52, pp. 43224–43235, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  200. S. E. Wahrle, H. Jiang, M. Parsadanian et al., “Deletion of Abca1 increases Aβ deposition in the PDAPP transgenic mouse model of Alzheimer disease,” Journal of Biological Chemistry, vol. 280, no. 52, pp. 43236–43242, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  201. H. Fukumoto, A. Deng, M. C. Irizarry, M. L. Fitzgerald, and G. W. Rebeck, “Induction of the cholesterol transporter ABCA1 in central nervous system cells by liver X receptor agonists increases secreted Aβ levels,” Journal of Biological Chemistry, vol. 277, no. 50, pp. 48508–48513, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  202. W. S. Kim, A. S. Rahmanto, A. Kamili et al., “Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein E discs and suppression of amyloid-β peptide generation,” Journal of Biological Chemistry, vol. 282, no. 5, pp. 2851–2861, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  203. J. Heeren, T. Grewal, A. Laatsch et al., “Impaired recycling of apolipoprotein E4 is associated with intracellular cholesterol accumulation,” Journal of Biological Chemistry, vol. 279, no. 53, pp. 55483–55492, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  204. R. Ehehalt, P. Keller, C. Haass, C. Thiele, and K. Simons, “Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts,” Journal of Cell Biology, vol. 160, no. 1, pp. 113–123, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  205. K. S. Vetrivel, H. Cheng, W. Lin et al., “Association of γ-secretase with lipid rafts in post-golgi and endosome membranes,” Journal of Biological Chemistry, vol. 279, no. 43, pp. 44945–44954, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  206. D. C. Fewlass, K. Noboa, F. X. Pi-Sunyer, J. M. Johnston, S. D. Yan, and N. Tezapsidis, “Obesity-related leptin regulates Alzheimer's Aβ,” FASEB Journal, vol. 18, no. 15, pp. 1870–1878, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  207. K. M. Mann, F. E. Thorngate, Y. Katoh-Fukui et al., “Independent effects of APOE on cholesterol metabolism and brain Aβ levels in an Alzheimer disease mouse model,” Human Molecular Genetics, vol. 13, no. 17, pp. 1959–1968, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  208. D. M. Mann, T. Iwatsubo, S. M. Pickering-Brown, F. Owen, T. C. Saido, and R. H. Perry, “Preferential deposition of amyloid beta protein (Abeta) in the form of Abeta40 in Alzheimer's disease associated with a gene dosage effect of the apolipoprotein E E4 allele,” Neurosci Lett, vol. 221, pp. 81–84, 1997.
  209. M. Morishima-Kawashima, N. Oshima, H. Ogata et al., “Effect of apolipoprotein E allele ε4 on the initial phase of amyloid β-protein accumulation in the human brain,” American Journal of Pathology, vol. 157, no. 6, pp. 2093–2099, 2000.
  210. H. Knoblauch, A. Bauerfeind, M. R. Toliat et al., “Haplotypes and SNPs in 13 lipid-relevant genes explain most of the genetic variance in high-density lipoprotein and low-density lipoprotein cholesterol,” Human Molecular Genetics, vol. 13, no. 10, pp. 993–1004, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  211. T. Isbir, B. Agaçhan, H. Yilmaz et al., “Apolipoprotein-E gene polymorphism and lipid profiles in Alzheimer's disease,” American Journal of Alzheimer's Disease and other Dementias, vol. 16, no. 2, pp. 77–81, 2001.
  212. J. M. Hagberg, K. R. Wilund, and R. E. Ferrell, “APO E gene and gene-environment effects on plasma lipoprotein-lipid levels,” Physiol Genomics, vol. 4, no. 2, pp. 101–108, 2000. View at Scopus
  213. J. Poirier, “Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease,” Neurobiology of Aging, vol. 26, no. 3, pp. 355–361, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  214. K. Höglund, O. Wiklund, H. Vanderstichele, O. Eikenberg, E. Vanmechelen, and K. Blennow, “Plasma Levels of β-amyloid(1-40), β-amyloid (1–42), and total β-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins,” Archives of Neurology, vol. 61, no. 3, pp. 333–337, 2004. View at Publisher · View at Google Scholar · View at PubMed
  215. Heart Protection Study Collaborative Group, “MRC/BHF Heart Protection study of cholesterol lowering with simvastatin in 20,506 high-risk individuals: a randomized placebo-controlled trial,” Lancet, vol. 360, pp. 7–22, 2002.
  216. J. Shepherd, G. J. Blauw, M. B. Murphy et al., “Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial,” Lancet, vol. 360, no. 9346, pp. 1623–1630, 2002. View at Publisher · View at Google Scholar
  217. T. Athanasopoulos, J. S. Owen, D. Hassall et al., “Intramuscular injection of a plasmid vector expressing human apolipoprotein E limits progression of xanthoma and aortic atheroma in apoE-deficient mice,” Human Molecular Genetics, vol. 9, no. 17, pp. 2545–2551, 2000. View at Scopus
  218. J. D. Harris, I. R. Graham, S. Schepelmann et al., “Acute regression of advanced and retardation of early aortic atheroma in immunocompetent apolipoprotein-E (apoE) deficient mice by administration of a second generation [E1-, E3-, polymerase-] adenovirus vector expressing human apoE,” Human Molecular Genetics, vol. 11, no. 1, pp. 43–58, 2002. View at Scopus
  219. H. V. Pai, R. P. Kommaddi, S. J. Chinta, T. Mori, M. R. Boyd, and V. Ravindranath, “A frameshift mutation and alternate splicing in human brain generate a functional form of the pseudogene cytochrome P4502D7 that demethylates codeine to morphine,” Journal of Biological Chemistry, vol. 279, no. 26, pp. 27383–27389, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  220. R. Cacabelos, World Guide for Drug Use and Pharmacogenomics, EuroEspes Publishing, Coruña, Spain, 2010.
  221. U. M. Zanger, M. Turpeinen, K. Klein, and M. Schwab, “Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation,” Analytical and Bioanalytical Chemistry, vol. 392, no. 6, pp. 1093–1108, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  222. Human Cytochrome P450 (CYP) Allele Nomenclature Committee, http://www.cypalleles.ki.se/.
  223. “The Pharmacogenomics Knowledge Base,” http://www.pharmgkb.org/.
  224. D. Frank, U. Jaehde, and U. Fuhr, “Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping,” European Journal of Clinical Pharmacology, vol. 63, no. 4, pp. 321–333, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  225. H. Shen, M. M. He, H. Liu et al., “Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17,” Drug Metabolism and Disposition, vol. 35, no. 8, pp. 1292–1300, 2007. View at Publisher · View at Google Scholar · View at PubMed
  226. S. Ozawa, A. Soyama, M. Saeki et al., “Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1,” Drug Metabolism and Pharmacokinetics, vol. 19, no. 2, pp. 83–95, 2004.
  227. C. Sachse, J. Brockmöller, S. Bauer, and I. Roots, “Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences,” American Journal of Human Genetics, vol. 60, no. 2, pp. 284–295, 1997. View at Scopus
  228. R. M. Weinshilboum and L. Wang, “Pharmacogenetics and pharmacogenomics: development, science, and translation,” Annual Review of Genomics and Human Genetics, vol. 7, pp. 223–245, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  229. S. L. Miksys and R. F. Tyndale, “Drug-metabolizing cytochrome P450s in the brain,” Journal of Psychiatry and Neuroscience, vol. 27, no. 6, pp. 406–415, 2002. View at Scopus
  230. I. Siegle, P. Fritz, K. Eckhardt, U. M. Zanger, and M. Eichelbaum, “Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain,” Pharmacogenetics, vol. 11, no. 3, pp. 237–245, 2001. View at Publisher · View at Google Scholar · View at Scopus
  231. A. Pilotto, M. Franceschi, G. D'Onofrio et al., “Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease,” Neurology, vol. 73, no. 10, pp. 761–767, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus